Background: CXCL-10 has been discovered as a pro-inflammatory chemokine that mediates leukocyte trafficking and modulates innate and adaptive immune responses after being demonstrated in the sera, synovial fluid (SF), and synovial tissue (ST) of cases with rheumatoid arthritis (RA). It contributes to several biologic processes and is essential to the inflammatory response. Objective: This study aimed to evaluate the predicative significance of chemokine CXCL10 in RA and to identify its relation to disease activity. Patients and Methods: 30 cases with RA and 30 healthy controls made up a case-control study. For each patient, a clinical examination was conducted. ELISA was utilized to measure the amount of CXCL10 in the blood, and the Disease Activity Score (DAS-28) that was utilized to assess the disease activity in the patients. Results: In terms of the blood level of CXCL-10, it was watched a high significant difference between the patients and controls with a high sensitivity and specificity in regard to RA diagnosis. According to the DAS-28, there was a significant difference between the different activity groups when CXCL-10 levels in patients with various grades of disease activity were compared.   Conclusion: Our research confirmed the pivotal function of CXCL10 in the RA inflammatory cascade and shown its importance as a biomarker for RA disease prediction. Additionally, it is essential for RA inflammation and might be a marker of disease activity in RA.